LAVAL, QC, Jan. 29 /CNW Telbec/ - Acasti Pharma Inc.today announced its
financial results for the three-month period and six-month period ended
November 30, 2008.
Acasti Pharma's President, Dr. Tina Sampalis pointed out that Acasti
Pharma started operations in August 2008 with the objective to advance the
pharmaceutical applications of its product portfolio in cardiovascular
In the fiscal quarter ended November 30, 2008, Acasti Pharma created a
loss of $234,000 and for the six-month period ended November 30, 2008, a loss
of $371,000. Acasti Pharma is researching and developing novel active
pharmaceutical ingredients for cardiovascular applications and the expenses
can be mainly attributed to R&D expenses and administrative expenses,
initially supported by the parent company Neptune Technologies & Bioressources
Acasti Pharma's fiscal year will end on February 28, 2009.
About Acasti Pharma Inc.
Acasti Pharma's product portfolio of proprietary novel long-chain omega-3
phospholipids are sourced from sustainable abundant marine biomass including
Antarctic krill (Euphausia superba). Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and
play, as such, an important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by potent antioxidants.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular
Acasti Pharma is a subsidiary of Neptune Technologies & Bioressources
Inc. (NASDAQ: NEPT; TSX.V:NTB).
NASDAQ does not accept responsibility for the adequacy or accuracy of
this press release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Acasti Pharma Inc., (450) 687-2262,